Faculty

Ronald K. Reeves, M.D.

Clinical Studies

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects with Acute Traumatic Cervical Spinal Cord Injury (Mitsubishi) Rochester, Minn.
The purpose of this study is to compare the effectiveness of intravenous (IV) infusions of MT-3921 to placebo in treatment of subjects with acute traumatic cervical spinal cord injury. The study assesses the effect of MT-3921 on sensory and motor impairment, prehension impairment, and functional outcomes and independence in activities of daily living and quality of life, the safety and tolerability of MT-3921, and will characterize the pharmacokinetics profile of MT-3921 following multiple-dose administration in subjects with spinal cord injury.
Minnesota Regional SCIMS (SCIMS) Rochester, Minn.
The purpose of this study is to contribute to the Spinal Cord Injury Model Systems (SCIMS) national database through longitudinal assessment of long-term health and psychosocial outcomes after acquired spinal cord injury (SCI).

Spasticity After Spinal Cord Injury Rochester, Minn.
A growing body of research demonstrates a correlation between residual corticospinal connectivity and severity of spasticity following SCI (Sangari et al., 2019b). The purpose of this study is to analyze this correlation to better understand the relationship between spasticity as a biomarker of residual corticospinal connectivity and neurologic and functional recovery.